PURPOSE: To describe the cost of treating diffuse large B-cell lymphoma (DLBCL) in Malawi under the following circumstances: (1) palliation only, (2) first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), (3) salvage etoposide, ifosfamide, and cisplatin (EPIC), and (4) salvage gemcitabine and oxaliplatin (GEMOX). METHODS: We conducted a microcosting analysis from the health system perspective in the context of a prospective cohort study at a national teaching hospital in Lilongwe, Malawi. Clinical outcomes data were derived from previously published literature from the cohort. Cost data were collected for treatment and 2-year follow-up, reflecting costs incurred by the research institution or referral hospital for goods and services. Costs were collected in Malawian kwacha, inflated and converted to 2017 US dollars. RESULTS: On a per-patient basis, palliative care alone cost $728 per person. Total costs for first-line treatment with CHOP chemotherapy was $1,844, of which chemotherapy drugs made up 15%. Separate salvage EPIC and GEMOX cost $2,597 and $3,176, respectively. Chemotherapy drugs accounted for 30% of EPIC and 47% of GEMOX. CONCLUSION: To our knowledge, this is among the first published efforts to characterize detailed costs of cancer treatment in sub-Saharan Africa. The per-patient cost of first-line treatment of DLBCL in Malawi is low relative to high-income countries, suggesting that investments in fixed-duration, curative-intent DLBCL treatment may be attractive in sub-Saharan Africa. Salvage treatment of relapsed/refractory DLBCL costs much more than first-line therapy. Formal cost-effectiveness modeling for CHOP and salvage treatment in the Malawian and other low-resource settings is needed to inform decision makers about optimal use of resources for cancer treatment.
PURPOSE: To describe the cost of treating diffuse large B-cell lymphoma (DLBCL) in Malawi under the following circumstances: (1) palliation only, (2) first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), (3) salvage etoposide, ifosfamide, and cisplatin (EPIC), and (4) salvage gemcitabine and oxaliplatin (GEMOX). METHODS: We conducted a microcosting analysis from the health system perspective in the context of a prospective cohort study at a national teaching hospital in Lilongwe, Malawi. Clinical outcomes data were derived from previously published literature from the cohort. Cost data were collected for treatment and 2-year follow-up, reflecting costs incurred by the research institution or referral hospital for goods and services. Costs were collected in Malawian kwacha, inflated and converted to 2017 US dollars. RESULTS: On a per-patient basis, palliative care alone cost $728 per person. Total costs for first-line treatment with CHOP chemotherapy was $1,844, of which chemotherapy drugs made up 15%. Separate salvage EPIC and GEMOX cost $2,597 and $3,176, respectively. Chemotherapy drugs accounted for 30% of EPIC and 47% of GEMOX. CONCLUSION: To our knowledge, this is among the first published efforts to characterize detailed costs of cancer treatment in sub-Saharan Africa. The per-patient cost of first-line treatment of DLBCL in Malawi is low relative to high-income countries, suggesting that investments in fixed-duration, curative-intent DLBCL treatment may be attractive in sub-Saharan Africa. Salvage treatment of relapsed/refractory DLBCL costs much more than first-line therapy. Formal cost-effectiveness modeling for CHOP and salvage treatment in the Malawian and other low-resource settings is needed to inform decision makers about optimal use of resources for cancer treatment.
Authors: Walter O Mwanda; Jackson Orem; Pingfu Fu; Cecilia Banura; Joweria Kakembo; Caren Auma Onyango; Anne Ness; Sherrie Reynolds; John L Johnson; Vivek Subbiah; Jacob Bako; Henry Wabinga; Fatuma K Abdallah; Howard J Meyerson; Christopher C Whalen; Michael M Lederman; Jodi Black; Leona W Ayers; Edward Katongole-Mbidde; Scot C Remick Journal: J Clin Oncol Date: 2009-05-26 Impact factor: 44.544
Authors: Norbert Schmitz; Samira Zeynalova; Maike Nickelsen; Roopesh Kansara; Diego Villa; Laurie H Sehn; Bertram Glass; David W Scott; Randy D Gascoyne; Joseph M Connors; Marita Ziepert; Michael Pfreundschuh; Markus Loeffler; Kerry J Savage Journal: J Clin Oncol Date: 2016-07-05 Impact factor: 44.544
Authors: Bongani Kaimila; Toon van der Gronde; Christopher Stanley; Edwards Kasonkanji; Maria Chikasema; Blessings Tewete; Paula Fox; Satish Gopal Journal: Infect Agent Cancer Date: 2017-08-09 Impact factor: 2.965
Authors: Rohina Joshi; Mohammed Alim; Andre Pascal Kengne; Stephen Jan; Pallab K Maulik; David Peiris; Anushka A Patel Journal: PLoS One Date: 2014-08-14 Impact factor: 3.240
Authors: Satish Gopal; Yuri Fedoriw; Bongani Kaimila; Nathan D Montgomery; Edwards Kasonkanji; Agnes Moses; Richard Nyasosela; Suzgo Mzumara; Carlos Varela; Maria Chikasema; Victor Makwakwa; Salama Itimu; Tamiwe Tomoka; Steve Kamiza; Bal M Dhungel; Fred Chimzimu; Coxcilly Kampani; Robert Krysiak; Kristy L Richards; Thomas C Shea; N George Liomba Journal: PLoS One Date: 2016-03-02 Impact factor: 3.240
Authors: Michael G Milligan; Elizabeth Bigger; Jeremy S Abramson; Aliyah R Sohani; Musimar Zola; Mukendi K A Kayembe; Heluf Medhin; Gita Suneja; Shahin Lockman; Bruce A Chabner; Scott L Dryden-Peterson Journal: J Glob Oncol Date: 2018-09